IL32 and inflammatory bowel disease: Therefore, this experiment's exploration of the distribution of these potential drug targets among IBD subtypes, especially those with a less well-established role in IBD such as IL-32 and the Th2-associated cytokines (IL-5, IL-13, IL-15, IL-33) offers insight into the design of studies developing the pharmacological intervention for IBD in the future.